Of note, most patients enrolled and therefore most responses observed were in patients with estrogen receptor (ER)-positive breast cancer, again underscoring the importance of not limiting evaluation of PARP inhibitors to TNBC. The gene discussed is ESR1; the disease is breast cancer.